EFX Sports Kre-Alkyayn Hardcore Thermogenic Creatine

Notify me when this product is available:

EFX Kre-Alkalyn Hardcore

EFX Kre-Alkalyn Hardcore is the definition of a three-headed monster. Improving strength, boosting energy, and slicing body fat. Leading the charge is the patented PH-correct Creatine Monohydrate. Allowing greater creatine absorption and increased bioavailability. No bloating, no cramping. Added ingredients to promote steady energy & focus. Holds thermogenic properties, speeding up the metabolism to burn stubborn body fat.  Getting that coveted six pack has never been easier. HARDCORE ENERGY, HARDCORE STRENGTH, HARDCORE FOCUS


EFX Kre-Alkalyn Hardcore Benefits:
  • Enhanced strength and muscular development

  • Improved energy and laser-sharp focus

  • Promotes thermogenesis, firing up the metabolism

  • Banned-substance free


EFX Kre-Alkalyn Hardcore Ingredient Breakdown:

Kre Alkalyn– a patented, pH correct creatine monohydrate. Improved absorption, greater strength gains, better recovery

Caffeine Anhydrous – for an energy boost and to increase performance

Green Coffee Extract– may promote fat burning and enhance exercise recovery  

Theobromine - helps boost blood flow and delivers sense of well-being

Theophylline ­– delays muscle fatigue

Razberi-K (raspberry ketones) - may provide a metabolic boost, helping burn body fat



Balestrino, Maurizio, and Enrico Adriano. “Beyond sports: Efficacy and safety of creatine supplementation in pathological or paraphysiological conditions of brain and muscle.” Medicinal research reviews vol. 39,6 (2019): 2427-2459. doi:10.1002/med.21590


Kerimi, Asimina, and Gary Williamson. “The cardiovascular benefits of dark chocolate.” Vascular pharmacology vol. 71 (2015): 11-5. doi:10.1016/j.vph.2015.05.011


Pigozzi, F et al. “Oral theophylline supplementation and high-intensity intermittent exercise.” The Journal of sports medicine and physical fitness vol. 43,4 (2003): 535-8.


Voduc, Nha et al. “Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study.” International journal of chronic obstructive pulmonary disease vol. 7 (2012): 245-52. doi:10.2147/COPD.S29990